Jens Kastrup

Medicine & Life Sciences

1. Mesenchymal Stem Cells 100%
2. Coronary Artery Disease 94%
3. Myocardial Ischemia 76%
4. Heart Failure 72%
5. Cell- and Tissue-Based Therapy 63%
6. Myocardial Infarction 62%
7. Stromal Cells 60%
8. Placebos 56%
9. Stem Cells 56%
10. ST Elevation Myocardial Infarction 48%
11. Coronary Disease 40%
12. Mortality 36%
13. Dilated Cardiomyopathy 36%
14. Granulocyte Colony-Stimulating Factor 35%
15. Vascular Endothelial Growth Factor A 34%
16. Angina Pectoris 34%
17. Perfusion 31%
18. Percutaneous Coronary Intervention 31%
19. Clarithromycin 30%
20. Therapeutics 29%
21. Biomarkers 29%
22. Leg 29%
23. Heart Transplantation 25%
24. Stroke Volume 25%
25. Injections 25%
26. Positron-Emission Tomography 24%
27. Lidocaine 22%
28. Heart 22%
29. Bone Marrow 21%
30. Hematopoietic Stem Cell Mobilization 21%
31. Myocardium 21%
32. Brain Natriuretic Peptide 21%
33. Ischemia 21%
34. Serum 20%
35. Adipose Tissue 20%
36. Skin 18%
37. Insulin 18%
38. Magnetic Resonance Imaging 16%
39. Arterial Pressure 16%
40. Regeneration 16%
41. Rubidium-82 16%
42. Safety 16%
43. Electrocardiography 15%
44. Endothelins 15%
45. Stents 15%
46. Left Ventricular Function 15%
47. Vascular Resistance 15%
48. 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane 15%
49. Cerebrovascular Circulation 15%
50. Bone Marrow Cells 14%